Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
neflamapimod
product3 mentionslast seen Oct 29, 2026
Oral small molecule drug candidate targeting neuroinflammation and neurodegeneration in age-related brain disorders.
Relationships 9
- CervoMed Inc.developsneflamapimod99% confidence3 sources
- neflamapimodapplies toamyotrophic lateral sclerosis treatment99% confidence3 sources
- neflamapimodapplies todementia with Lewy bodies treatment99% confidence3 sources
- U.S. Food and Drug Administrationapprovesneflamapimod99% confidence2 sources
- neflamapimoddepends onp38 MAP kinase inhibition99% confidence2 sources
- neflamapimodapplies toischemic stroke recovery99% confidence2 sources
- neflamapimodapplies tononfluent variant primary progressive aphasia treatment95% confidence1 source
- neflamapimodapplies tonon-fluent variant primary progressive aphasia treatment95% confidence1 source
- neflamapimodapplies toprimary progressive aphasia treatment80% confidence1 source
Relationship
CervoMed Inc.developsneflamapimod
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGAROct 29, 2026CervoMed Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
CervoMed Inc. developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod
- filingSEC EDGAROct 13, 2026CervoMed Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
CervoMed Inc. announced initial data showing a reduction in mean plasma levels of neurofilament light chain (NfL), a key biomarker of neuronal damage and degeneration, over the first 12 weeks of treatment with neflamapimod
- filingSEC EDGARSep 28, 2026CervoMed Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod